AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29384903 — intervention group
Group type: COMPARATOR
Intervention: linezolid 600 mg twice daily for 10 days
Number of subjects: 813
Study 25449222 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Health and Development Program (intervention)
Number of subjects: 875
Study 24210590 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs) losartan
Number of subjects: 3238
Study 24210590 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs) irbesartan
Number of subjects: 3238
Study 24210590 — intervention group
Group type: COMPARATOR
Intervention: Confirmed eGFR decline of 57%, 40%, 30%, or 20%
Number of subjects: 3238
Study 24210590 — intervention group
Group type: COMPARATOR
Intervention: Confirmed doubling of serum creatinine level
Number of subjects: 3238
Study 21496112 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training for wrist extensors with a forearm band, 6-week home exercise regimen.
Number of subjects: 42
Study 21496112 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a forearm band only.
Number of subjects: 42
Study 20629516 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic shear as a single working instrument, two-trocar technique (group 1 = 80 patients)
Number of subjects: 160
Study 20629516 — intervention group
Group type: COMPARATOR
Intervention: Regular clip/cautery, three-trocar technique (group 2 = 80 patients)
Number of subjects: 160
Study 17694461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (100 microg/min for 12 hours after PCI)
Number of subjects: 200
Study 17694461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 200
Study 15662235 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue antihypertensive therapy
Number of subjects: 2900
Study 15662235 — intervention group
Group type: COMPARATOR
Intervention: Stop antihypertensive therapy
Number of subjects: 2900
Study 11985763 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 0.8 mg four times daily for 2 weeks
Number of subjects: 15
Study 11985763 — intervention group
Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 15
Study 11985763 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study 9496408 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine 3.0 g (single dose)
Number of subjects: 0
Study 9496408 — intervention group
Group type: COMPARATOR
Intervention: Standard agents (nitrofurantoin, norfloxacin, trimethoprim/sulfamethoxazole)
Number of subjects: 0
Study 8701877 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training on a cycle ergometer 3 times a week for 8 weeks at 60% of peak oxygen uptake (Group T)
Number of subjects: 43
Study 8701877 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 43
Study 1876465 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 42
Study 1876465 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMX and prednisone
Number of subjects: 42
Study 1876465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6299050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil, 400 mg/day
Number of subjects: 10
Study 6299050 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens, 1.25 mg/day
Number of subjects: 10
Study 30852538 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Safe Link
Number of subjects: 434
Study 30852538 — intervention group
Group type: COMPARATOR
Intervention: Stay Safe
Number of subjects: 434
Study 28112473 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCEL2 stent
Number of subjects: 833
Study 27959333 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose of dexamethasone
Number of subjects: 0
Study 24812304 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 1663
Study 24812304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1663
Study 22657254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + FOLFIRI
Number of subjects: 0
Study 22657254 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 0
Study 19948811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cardiovascular risk management including risk assessment, risk communication, a decision aid and adapted motivational interviewing
Number of subjects: 615
Study 19948811 — intervention group
Group type: COMPARATOR
Intervention: Minimal nurse-led intervention (Control)
Number of subjects: 615
Study 17589976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1 MAC end‐tidal concentration)
Number of subjects: 32
Study 17589976 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2 to 3 mg kg(‐1) hour(‐1))
Number of subjects: 32
Study 15502598 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10‐50 mg/day)
Number of subjects: 207
Study 15502598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 15502598 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 207
Study 11434074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational pamphlet ('Early Prostate Cancer')
Number of subjects: 342
Study 11434074 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 342
Study 9753251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (300 mg three times a day) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Number of subjects: 120
Study 9753251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rebamipide) with omeprazole (40 mg twice a day) and amoxicillin (1500 mg three times a day)
Number of subjects: 120
Study 8665047 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 8
Study 8665047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2680275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841
Study 2680275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841
Study 2680275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841
Study 2680275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841
Study 2680275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study 987578 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 987578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29474685 — intervention group
Group type: EXPERIMENTAL
Intervention: HealtheSteps™ lifestyle prescription program (in-person coaching sessions, goal setting and tracking, technology supports)
Number of subjects: 25
Study 29474685 — intervention group
Group type: EXPERIMENTAL
Intervention: HealtheSteps™ lifestyle prescription program
Number of subjects: 25
Study 28605781 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free arm (everolimus with mycophenolic acid)
Number of subjects: 499
Study 28605781 — intervention group
Group type: EXPERIMENTAL
Intervention: low-CNI group (everolimus with reduced CNI)
Number of subjects: 499
Study 28605781 — intervention group
Group type: COMPARATOR
Intervention: standard CNI group (cyclosporine with mycophenolic acid)
Number of subjects: 499
Study 26342289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal AZD8848 20 µg three times weekly
Number of subjects: 83
Study 26342289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal AZD8848 60 µg once weekly
Number of subjects: 83
Study 26342289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 23455335 — intervention group
Group type: EXPERIMENTAL
Intervention: Goat milk formula
Number of subjects: 90
Study 23455335 — intervention group
Group type: COMPARATOR
Intervention: Cow milk-based formula
Number of subjects: 90
Study 23455335 — intervention group
Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 90
Study 21205592 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with drug eluting stents
Number of subjects: 80
Study 21205592 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 80
Study 18285440 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 0
Study 18285440 — intervention group
Group type: COMPARATOR
Intervention: Randomized treatments
Number of subjects: 0
Study 16438980 — intervention group
Group type: EXPERIMENTAL
Intervention: Question repetition (questions asked three times)
Number of subjects: 136
Study 12589445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior word length cuing
Number of subjects: 0
Study 12589445 — intervention group
Group type: EXPERIMENTAL
Intervention: Target word frequency (high or low)
Number of subjects: 0
Study 12589445 — intervention group
Group type: EXPERIMENTAL
Intervention: Exterior letters consistency (large or small pool of candidate words)
Number of subjects: 0
Study 10699160 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1.0 mg per kilogram of body weight), given intravenously within 24 hours after surgery and every two weeks thereafter for a total of five doses
Number of subjects: 55
Study 10699160 — intervention group
Group type: COMPARATOR
Intervention: Generalized immunosuppressive therapy (control group)
Number of subjects: 55
Study 10699160 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 55
Study 9124468 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg 30 min before and 0.75 mg 120 min after light exposure)
Number of subjects: 10
Study 9124468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8166887 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg (n = 61)
Number of subjects: 125
Study 8166887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 125
Study 3535392 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil rich in gammalinolenic acid (GLA, 18:3 n‐6) (n = 13)
Number of subjects: 27
Study 3535392 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil concentrate containing n‐3 fatty acids (n = 14)
Number of subjects: 27
Study 3535392 — intervention group
Group type: COMPARATOR
Intervention: Olive oil as placebo
Number of subjects: 27
Study 29878825 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention (12-month follow-up support)
Number of subjects: 249
Study 29878825 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 249
Study 27825059 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Number of subjects: 0
Study 27825059 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical treatment
Number of subjects: 0
Study 25211359 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin solution with 20% dextran
Number of subjects: 27
Study 25211359 — intervention group
Group type: COMPARATOR
Intervention: Dextran-free riboflavin solution
Number of subjects: 27
Study 22687313 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 25
Study 22687313 — intervention group
Group type: COMPARATOR
Intervention: Control (antibiotic therapy only)
Number of subjects: 25
Study 19878147 — intervention group
Group type: EXPERIMENTAL
Intervention: CR = 25% caloric restriction
Number of subjects: 43
Study 19878147 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + EX = 12.5% CR + 12.5% increase in energy expenditure by structured exercise
Number of subjects: 43
Study 19878147 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD = low calorie diet until 15% weight reduction followed by weight maintenance
Number of subjects: 43
Study 19878147 — intervention group
Group type: COMPARATOR
Intervention: Control = 100% of energy requirements
Number of subjects: 43
Study 17533467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled-tip catheter (n=26)
Number of subjects: 52
Study 17533467 — intervention group
Group type: COMPARATOR
Intervention: 8 mm-tip catheter (n=26)
Number of subjects: 52
Study 16243989 — intervention group
Group type: EXPERIMENTAL
Intervention: ODT ondansetron 8 mg
Number of subjects: 150
Study 16243989 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ondansetron 4 mg
Number of subjects: 150
Study 16243989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 12108616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous porcine secretin
Number of subjects: 0
Study 12108616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10665675 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-aided therapy during acute rehabilitation
Number of subjects: 20
Study 10665675 — intervention group
Group type: COMPARATOR
Intervention: Standard acute rehabilitation treatment
Number of subjects: 20
Study 7885806 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving visual stimulus
Number of subjects: 0
Study 7885806 — intervention group
Group type: COMPARATOR
Intervention: Stationary surround
Number of subjects: 0
Study 7885806 — intervention group
Group type: COMPARATOR
Intervention: No-vision condition
Number of subjects: 0
Study 7885806 — intervention group
Group type: EXPERIMENTAL
Intervention: Surround velocities between 4 and 40 degrees/sec
Number of subjects: 0
Study 2533023 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg/die for 14 days)
Number of subjects: 63
Study 2533023 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam beta-cyclodextrin (20 mg/die for 14 days)
Number of subjects: 63
Study 30083399 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter(R) device
Number of subjects: 40
Study 30083399 — intervention group
Group type: COMPARATOR
Intervention: Active Cycle of Breathing Techniques (ACBT)
Number of subjects: 40
Study 28749822 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV(+) with cHB
Number of subjects: 2463
Study 28749822 — intervention group
Group type: COMPARATOR
Intervention: HIV(+) without cHB
Number of subjects: 2463
Study 28749822 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV(+)
Number of subjects: 2463
Study 28749822 — intervention group
Group type: COMPARATOR
Intervention: HIV(‐)
Number of subjects: 2463
Study 24413071 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day physical plus cognitive exercise group (two 60-min sessions a week of aerobic and cognitive exercises)
Number of subjects: 138
Study 24413071 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day exercise group (two 60-min sessions a week of aerobic exercises)
Number of subjects: 138
Study 24413071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study 24294744 — intervention group
Group type: EXPERIMENTAL
Intervention: Local probiotics vaginal medicine (10 applications) containing Lactobacillus acidophilus and Lactobacillus rhamnosus
Number of subjects: 381
Study 24294744 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day)
Number of subjects: 381
Study 24294744 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg BID for 5 days) + 2 vaginal ovules of Metronidazole (1000 mg each, every other day) + local probiotics (starting day 5)
Number of subjects: 381
Study 21569374 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary ovarian suspension (elevating both ovaries to the anterior abdominal wall using a Prolene suture) post-operatively
Number of subjects: 0
Study 21569374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (a new transabdominal suture reinserted to act as a placebo)
Number of subjects: 0
Study 19450759 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cyclosporine-A (CsA) on day -7
Number of subjects: 152
Study 19450759 — intervention group
Group type: COMPARATOR
Intervention: Conventional cyclosporine-A (CsA) on day -1
Number of subjects: 152
Study 17030174 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a plus ribavirin
Number of subjects: 516
Study 17030174 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon alfa alone
Number of subjects: 516
Study 14628238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet released before wound closure
Number of subjects: 70
Study 14628238 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet released after wound closure
Number of subjects: 70
Study 11134099 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 50 mg/day
Number of subjects: 227
Study 11134099 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 100 mg/day
Number of subjects: 227
Study 11134099 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 50 mg to 75 mg/day
Number of subjects: 227
Study 11134099 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel 100 mg to 75 mg/day
Number of subjects: 227
Study 11134099 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (both doses)
Number of subjects: 227
Study 11134099 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel
Number of subjects: 227
Study 11134099 — intervention group
Group type: COMPARATOR
Intervention: Transdermal testosterone patch (2 patches delivering 5 mg T/day)
Number of subjects: 227
Study 9307537 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of prostaglandin E2 (2 mg)
Number of subjects: 955
Study 9307537 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of prostaglandin E2 (2 mg each, second dose after six hours if needed)
Number of subjects: 955
Study 9307537 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of prostaglandin E2 (2 mg each)
Number of subjects: 955
Study 8349432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral menogaril (85 mg/m2 to 625 mg/m2 every 4 weeks)
Number of subjects: 47
Study 8349432 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating oral and IV menogaril (250 mg/m2 IV; 250-500 mg/m2 oral)
Number of subjects: 47
Study 8349432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral menogaril
Number of subjects: 47
Study 8349432 — intervention group
Group type: EXPERIMENTAL
Intervention: IV menogaril
Number of subjects: 47
Study 3525736 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (one-week course)
Number of subjects: 52
Study 3525736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29439844 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit immediately group (n=50)
Number of subjects: 100
Study 29439844 — intervention group
Group type: COMPARATOR
Intervention: Cut down to quit group (n=50)
Number of subjects: 100
Study 26403265 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C (APC)
Number of subjects: 20
Study 26403265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24326361 — intervention group
Group type: EXPERIMENTAL
Intervention: NCB®‐DF (polyaxial locking plates)
Number of subjects: 27
Study 24326361 — intervention group
Group type: COMPARATOR
Intervention: LISS® (monoaxial locking plates)
Number of subjects: 27
Study 22471138 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming‐promotion needling technique
Number of subjects: 30
Study 22471138 — intervention group
Group type: COMPARATOR
Intervention: Routine needling technique
Number of subjects: 30
Study 21254734 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP (Transurethral Resection of the Prostate)
Number of subjects: 0
Study 19068454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, 4 weeks 'on' and 2 weeks 'off')
Number of subjects: 0
Study 19068454 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 19068454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 16789966 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15272999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention pride orientation in HRS individuals
Number of subjects: 0
Study 15272999 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived rejection in HRS individuals high in prevention pride
Number of subjects: 0
Study 10937788 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-administered SCL-90-R
Number of subjects: 282
Study 10937788 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil SCL-90-R
Number of subjects: 282
Study 9350186 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 0
Study 9350186 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 0
Study 9350186 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical regimen modification
Number of subjects: 0
Study 9350186 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic episodes with clinically defined infection
Number of subjects: 0
Study 9350186 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenic episodes without a focus
Number of subjects: 0
Study 8146033 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg maprotiline
Number of subjects: 20
Study 8146033 — intervention group
Group type: COMPARATOR
Intervention: 500 mg aminophylline
Number of subjects: 20
Study 2873974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidamidine (10 mg per os)
Number of subjects: 5
Study 2873974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31837126 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-led exercise
Number of subjects: 1083
Study 31837126 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced exercise-based care
Number of subjects: 1083
Study 31837126 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise-based care
Number of subjects: 1083
Study 29986611 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of elcatonin (EL group)
Number of subjects: 869
Study 29986611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 869
Study 28249107 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dissonance-based eating disorder program
Number of subjects: 47